乐城海南眼视光眼科医院招募眼疾患者开展真实世界研究

Core Insights - The Hainan Eye Hospital has introduced the 0.19 fluocinolone acetonide intravitreal implant, a unique FDA-approved drug for treating diabetic macular edema (DME), leveraging the "pilot" policy of the Boao Lecheng International Medical Tourism Pilot Zone [1] - The hospital is recruiting 121 DME patients nationwide for a real-world effectiveness study, with the first patient already injected on August 1 [2] Group 1 - The 0.19 fluocinolone acetonide implant is a non-biodegradable injectable corticosteroid that provides sustained release for up to three years, specifically for DME treatment [1] - DME is a common complication of diabetes, often affecting both eyes, leading to significant treatment and economic burdens for patients [1] - The new implant aims to help DME patients manage macular edema over the long term, maintain vision, and reduce the frequency of medical visits [1]